TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
1.110
+0.020 (1.83%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States.
It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names.
The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
TherapeuticsMD, Inc.
Country | United States |
Founded | 2008 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 1 |
CEO | Marlan Walker |
Contact Details
Address: 951 Yamato Road, Suite 220 Boca Raton, Florida 33431 United States | |
Phone | 561 961 1900 |
Website | therapeuticsmd.com |
Stock Details
Ticker Symbol | TXMD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000025743 |
CUSIP Number | 88338N206 |
ISIN Number | US88338N2062 |
Employer ID | 87-0233535 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Marlan D. Walker J.D. | Chief Executive Officer |
Governor Thomas G. Thompson | Executive Chairman |
Joseph A. Ziegler | Principal Financial and Accounting Officer |
Douglas Steelman | Vice President of Market Access |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 5, 2024 | 8-K | Current Report |
Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Nov 12, 2024 | 10-Q | Quarterly Report |
Nov 12, 2024 | 8-K | Current Report |
Oct 25, 2024 | ARS | Filing |
Oct 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Oct 25, 2024 | DEF 14A | Other definitive proxy statements |
Sep 20, 2024 | 8-K | Current Report |
Aug 12, 2024 | 10-Q | Quarterly Report |
Aug 12, 2024 | 8-K | Current Report |